Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC.
Alessi JV, Wang X, Elkrief A, Ricciuti B, Li YY, Gupta H, Spurr LF, Rizvi H, Luo J, Pecci F, Lamberti G, Recondo G, Venkatraman D, Di Federico A, Gandhi MM, Vaz VR, Nishino M, Sholl LM, Cherniack AD, Ladanyi M, Price A, Richards AL, Donoghue M, Lindsay J, Sharma B, Turner MM, Pfaff KL, Felt KD, Rodig SJ, Lin X, Meyerson ML, Johnson BE, Christiani DC, Schoenfeld AJ, Awad MM. Alessi JV, et al. Among authors: di federico a. J Thorac Oncol. 2023 Nov;18(11):1524-1537. doi: 10.1016/j.jtho.2023.05.019. Epub 2023 May 27. J Thorac Oncol. 2023. PMID: 37247843 Free PMC article.
Advanced non-small-cell lung cancer: how to manage non-oncogene disease.
De Giglio A, Di Federico A, Deiana C, Ricciuti B, Brambilla M, Metro G. De Giglio A, et al. Among authors: di federico a. Drugs Context. 2022 Jul 8;11:2022-2-4. doi: 10.7573/dic.2022-2-4. eCollection 2022. Drugs Context. 2022. PMID: 35912001 Free PMC article. Review.
Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease.
Metro G, De Giglio A, Ricciuti B, Siringo M, Marinelli D, Gelibter A, Pecci F, Berardi R, Cantini L, Di Federico A, Andrini E, Mosca M, Lamberti G, Brambilla M, Mountzios G. Metro G, et al. Among authors: di federico a. Drugs Context. 2022 Jul 29;11:2022-3-9. doi: 10.7573/dic.2022-3-9. eCollection 2022. Drugs Context. 2022. PMID: 35975031 Free PMC article. Review.
Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma.
Scalera S, Ricciuti B, Mazzotta M, Calonaci N, Alessi JV, Cipriani L, Bon G, Messina B, Lamberti G, Di Federico A, Pecci F, Milite S, Krasniqi E, Barba M, Vici P, Vecchione A, De Nicola F, Ciuffreda L, Goeman F, Fanciulli M, Buglioni S, Pescarmona E, Sharma B, Felt KD, Lindsay J, Rodig SJ, De Maria R, Caravagna G, Cappuzzo F, Ciliberto G, Awad MM, Maugeri-Saccà M. Scalera S, et al. Among authors: di federico a. Ann Oncol. 2023 Mar;34(3):275-288. doi: 10.1016/j.annonc.2022.12.002. Epub 2022 Dec 13. Ann Oncol. 2023. PMID: 36526124 Free article.
Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC.
Alessi JV, Elkrief A, Ricciuti B, Wang X, Cortellini A, Vaz VR, Lamberti G, Frias RL, Venkatraman D, Fulgenzi CAM, Pecci F, Recondo G, Di Federico A, Barrichello A, Park H, Nishino M, Hambelton GM, Egger JV, Ladanyi M, Digumarthy S, Johnson BE, Christiani DC, Lin X, Gainor JF, Lin JJ, Pinato DJ, Schoenfeld AJ, Awad MM. Alessi JV, et al. Among authors: di federico a. J Thorac Oncol. 2023 Jun;18(6):731-743. doi: 10.1016/j.jtho.2023.01.091. Epub 2023 Feb 10. J Thorac Oncol. 2023. PMID: 36775193 Free PMC article.
Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non-Small Cell Lung Cancer.
Ricciuti B, Elkrief A, Alessi J, Wang X, Li Y, Gupta H, Muldoon DM, Bertram AA, Pecci F, Lamberti G, Di Federico A, Barrichello A, Vaz VR, Gandhi M, Lee E, Shapiro GI, Park H, Nishino M, Lindsay J, Felt KD, Sharma B, Cherniack AD, Rodig S, Gomez DR, Shaverdian N, Rakaee M, Bandlamudi C, Ladanyi M, Janne PA, Schoenfeld AJ, Sholl LM, Awad MM, Cheng ML. Ricciuti B, et al. Among authors: di federico a. Clin Cancer Res. 2023 Jul 5;29(13):2540-2550. doi: 10.1158/1078-0432.CCR-22-3413. Clin Cancer Res. 2023. PMID: 37097610 Free PMC article.
Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer.
Di Federico A, Ricciotti I, Favorito V, Michelina SV, Scaparone P, Metro G, De Giglio A, Pecci F, Lamberti G, Ambrogio C, Ricciuti B. Di Federico A, et al. Curr Oncol Rep. 2023 Sep;25(9):1017-1029. doi: 10.1007/s11912-023-01436-y. Epub 2023 Jun 28. Curr Oncol Rep. 2023. PMID: 37378881 Review.
Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer.
Thummalapalli R, Ricciuti B, Bandlamudi C, Muldoon D, Rizvi H, Elkrief A, Luo J, Alessi JV, Pecci F, Lamberti G, Di Federico A, Hong L, Zhang J, Heymach JV, Gibbons DL, Plodkowski AJ, Ravichandran V, Donoghue MTA, Vanderbilt C, Ladanyi M, Rudin CM, Kris MG, Riely GJ, Chaft JE, Hellmann MD, Vokes NI, Awad MM, Schoenfeld AJ. Thummalapalli R, et al. Among authors: di federico a. Clin Cancer Res. 2023 Nov 1;29(21):4408-4418. doi: 10.1158/1078-0432.CCR-23-1207. Clin Cancer Res. 2023. PMID: 37432985 Free PMC article.
63 results